Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 2
1999 1
2002 1
2003 2
2008 3
2009 1
2010 7
2011 5
2012 5
2013 4
2014 1
2015 2
2016 4
2017 5
2018 2
2019 3
2020 5
2021 4
2022 3
2023 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
[Update on Current Care Guideline: Parkinson's disease].
Pekkonen E, Atula S, Autere J, Eerola-Rautio J, Kaasinen V, Kauppinen M, Martikainen K, Ruottinen H, Viljamaa M. Pekkonen E, et al. Among authors: atula s. Duodecim. 2016;132(1):91-3. Duodecim. 2016. PMID: 27044185 Finnish.
Hemiplegia and thrombolysis.
Meretoja A, Strbian D, Putaala J, Kaste M, Tatlisumak T; Helsinki Stroke Thrombolysis Registry Group. Meretoja A, et al. Eur J Neurol. 2012 Sep;19(9):1235-8. doi: 10.1111/j.1468-1331.2012.03729.x. Epub 2012 Apr 23. Eur J Neurol. 2012. PMID: 22519602
Cardiac manifestations in Finnish gelsolin amyloidosis patients.
Mustonen T, Holkeri A, Holmström M, Atula S, Pakarinen S, Lehmonen L, Kiuru-Enari S, Aro AL. Mustonen T, et al. Among authors: atula s. Amyloid. 2021 Sep;28(3):168-172. doi: 10.1080/13506129.2021.1911798. Epub 2021 Apr 20. Amyloid. 2021. PMID: 33877023
Natural course of Finnish gelsolin amyloidosis.
Nikoskinen T, Schmidt EK, Strbian D, Kiuru-Enari S, Atula S. Nikoskinen T, et al. Among authors: atula s. Ann Med. 2015;47(6):506-11. doi: 10.3109/07853890.2015.1075063. Epub 2015 Sep 4. Ann Med. 2015. PMID: 26339870 Free article.
Hearing problems in patients with hereditary gelsolin amyloidosis.
Mustonen T, Sivonen V, Atula S, Kiuru-Enari S, Sinkkonen ST. Mustonen T, et al. Among authors: atula s. Orphanet J Rare Dis. 2021 Oct 24;16(1):448. doi: 10.1186/s13023-021-02077-9. Orphanet J Rare Dis. 2021. PMID: 34689817 Free PMC article.
59 results